23andme and the fda reached a pivotal genetic testing agreement /

The FDA opens the door for personal genetics company 23andMe to sell tests for Bloom syndrome.
An FDA decision summary released today allows DNA-testing company 23andMe to market a genome test that screens for Bloom syndrome,a rare disorder that leads to a predisposition in carriers toward the development of cancer. While, on the surface, and this may seem like a minor change in policy,it is meaningful given the complex relationship the FDA has had with 23andMe over the final two years.
Read Full sage






Source: fastcompany.com